Christina Johnson

Christina (Chang) Johnson is an experienced executive in the pharmaceutical and biotechnology industries, currently serving as Executive Director of Global Commercial Product Strategy at Gilead Sciences since June 2022, where Christina (Chang) leads the global commercialization team for Livdelzi in PBC. Prior to this, Christina held a Senior Director position at Gilead, managing the global commercial strategy for a late-stage oncology asset. Christina also has experience as Director of Marketing at Nektar Therapeutics, leading immuno-oncology product launches, and in multiple roles at Genentech, where significant contributions included launching TECENTRIQ for cancer immunotherapy. Additional experience includes consulting roles at Booz Allen Hamilton and Putnam Associates, as well as research at Rock Health. Christina earned an MBA from the University of California, Berkeley, Haas School of Business, and a BS in Economics and Chinese from Duke University.